Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kao Develops New Ingredients Effective against Wrinkles
August 27, 2001
- Korosho Asks Bayer, Takeda to Take Safety Measures Regarding Cerivastatin
August 27, 2001
- Efco, Kyuyukai Postpone Merger to Next Fiscal Year
August 27, 2001
- Korosho to Listen to Industry's Opinions on Amending PAL
August 27, 2001
- Pharmacists Are Absent from 64% of Stores Selling Drugs at Night
August 27, 2001
- Price Adjustment Method No Longer Functions Properly: Mr Fujii, New Diet Member
August 27, 2001
- OCT NEWS IN BRIEF
August 27, 2001
- Economic Reform Should Not Affect Quality of Social Security Services: Mr Takemi, Lower House Member
August 27, 2001
- Yamanouchi Discovers Immunocompetent Cell Activating Gene
August 27, 2001
- Canopus Develops New Image Distribution System for Hospitals
August 20, 2001
- BUSINESS NEWS IN BRIEF -1-
August 20, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 20, 2001
- BUSINESS NEWS IN BRIEF -2-
August 20, 2001
- Takara Launches 2 Additional DNA Chips
August 20, 2001
- Savings of \1.4 Trillion Possible by Reducing Drug Cost to 16%: Council Report
August 20, 2001
- Study on Diagnostic Method Using PALSAR Selected by JHSF
August 20, 2001
- 6th Designation for Quality Reevaluation Approved
August 20, 2001
- Takeda, Pharmacia to Launch Smoking Cessation Aid Nicorette in September
August 20, 2001
- Tiracoxib Designated as Orphan for Familial Adenomatous Polyposis
August 20, 2001
- Asahi Kasei Licenses Out Fasudil to Schering AG
August 20, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…